Clinical Trial: NCT02213926
An Open-label, Phase 2 Study of ACP-196 (Acalabrutinib) in Subjects With Mantle Cell Lymphoma
Status:
ACTIVE NOT RECRUITINGPhase:
Phase 2| Lead Sponsor: | Acerta Pharma BV |
| Information Provided By: | Acerta Pharma BV |
| Last Update Posted: | 2026-08-04 |
Study Overview
Brief Summary
The purpose of this study is to characterize the safety and efficacy profile of ACP-196 (acalabrutinib) in subjects with relapsed or refractory Mantle Cell Lymphoma (MCL).
Official Title
An Open-label, Phase 2 Study of ACP-196 in Subjects With Mantle Cell Lymphoma
Conditions
Mantle Cell Lymphoma (MCL)
Intervention / Treatment
- Drug: ACP-196 (acalabrutinib)
Other Study ID Numbers
- ACE-LY-004
- 2023-509352-34-00
- 2014-002117-28
- 2014
- 2023
Start Date (Actual)
2015-03-02
Primary Completion Date (Actual)
2020-12-04
Study Completion Date (Estimated)
2026-09-06
Enrollment (Actual)
124
Study Type
Interventional
Phase
Phase 2
| Lead Sponsor: | Acerta Pharma BV |
| Information Provided By: | Acerta Pharma BV |
| Last Update Posted: | 2026-08-04 |
Study Overview
Brief Summary
The purpose of this study is to characterize the safety and efficacy profile of ACP-196 (acalabrutinib) in subjects with relapsed or refractory Mantle Cell Lymphoma (MCL).
Official Title
An Open-label, Phase 2 Study of ACP-196 in Subjects With Mantle Cell Lymphoma
Conditions
Mantle Cell Lymphoma (MCL)
Intervention / Treatment
- Drug: ACP-196 (acalabrutinib)
Other Study ID Numbers
- ACE-LY-004
- 2023-509352-34-00
- 2014-002117-28
- 2014
- 2023
Start Date (Actual)
2015-03-02
Primary Completion Date (Actual)
2020-12-04
Study Completion Date (Estimated)
2026-09-06
Enrollment (Actual)
124
Study Type
Interventional
Phase
Phase 2